GlassScriptPhysician profile
Alan G Carnell
NPI 1548255649
$1,580.89
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $120 · 2021: $352 · 2022: $468 · 2023: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $499.22 | 2019-2023 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.36 | 2019-2022 | |
| Janssen Biotech, INC. | $216.19 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.85 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $90.70 | 2019-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $76.52 | 2019-2023 | Ocaliva |
| Celgene Corporation | $67.14 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $60.24 | 2021-2023 | |
| Ucb, INC. | $38.18 | 2019 | |
| Genzyme Corporation | $26.22 | 2022-2023 | |
| Pfizer INC. | $25.86 | 2019 | |
| Boston Scientific Corporation | $19.69 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.29 | 2022 | |
| Merck Sharp & Dohme LLC | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Carnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.